Search results
Results from the WOW.Com Content Network
Pseudohyperaldosteronism (also pseudoaldosteronism) is a medical condition which mimics the effects of elevated aldosterone (hyperaldosteronism) by presenting with high blood pressure, low blood potassium levels (hypokalemia), metabolic alkalosis, and low levels of plasma renin activity (PRA).
It appears to provide more accuracy in identifying early prostate cancer than the standard prostate cancer marker, PSA. "EPCA-2" is not the name of a gene. EPCA-2 gets its name because it is the second prostate cancer marker identified by the research team. This earlier marker was previously known as "EPCA", [1] [2] but is now called "EPCA-1".
A biomarker may be used to see how well the body responds to a treatment for a disease or condition. Also called molecular marker and signature molecule." [18] In cancer research and medicine, biomarkers are used in three primary ways: [19] To help diagnose conditions, as in the case of identifying early stage cancers (diagnostic)
Tumor markers may be used for the following purposes: Monitoring the malignancy; When a malignant tumor is found by the presence of a tumor marker, the level of marker found in the body can be monitored to determine the state of the tumor and how it responds to treatment. If the quantity stays the same during treatment it can indicate that the ...
Processing of tumor antigens recognized by CD8+ T cells. Normal proteins in the body are not antigenic because of self-tolerance, a process in which self-reacting cytotoxic T lymphocytes (CTLs) and autoantibody-producing B lymphocytes are culled "centrally" in primary lymphatic tissue (BM) and "peripherally" in secondary lymphatic tissue (mostly thymus for T-cells and spleen/lymph nodes for B ...
The reviews couldn’t be more glowing — from senior dogs to horses and hogs, customers love this product. See what they’re crowing about at Quick Feed . Find it for $330.
21-Deoxycorticosterone, also known as 11β-hydroxyprogesterone (11β-OHP), have been proposed as a marker in 1987. [181] [182] A study in 2017 has shown that in subjects with 21-hydroxylase deficiency, serum 11β-OHP concentrations range from 0.012 to 3.37 ng/mL, while in control group it was below detection limit of 0.012 ng/mL. [38]
An analysis of a sample of comments carried out by market research firm OneCliq found the vast majority - four-fifths - contained criticism of the healthcare system.